Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings plc reported insider transactions by Chief HR Officer Tina Amber St Leger. On February 18, 2026, she completed an open-market sale of 1,000 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
On February 17, 2026, 2,119 Restricted Share Units were exercised and converted into 2,119 Ordinary Shares at no cost, with each RSU representing one Ordinary Share. After these transactions, she directly held 1,119 Ordinary Shares and 6,357 RSUs.
Immunocore Holdings plc’s Head of R&D, David M. Berman, reported RSU vesting, share issuance and a related tax sale. On February 17, 2026, he exercised 11,824 Restricted Share Units, receiving the same number of Ordinary Shares at a $0.00 exercise price.
On February 18, 2026, he conducted an open-market sale of 5,965 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from RSU vesting. After these transactions, he directly held 5,859 Ordinary Shares and 35,473 RSUs. Each RSU and each American Depositary Share represents one Ordinary Share.
Immunocore plc reported planned insider stock sales via Form 144. The filing lists multiple proposed disposals of American Depositary Receipts (ADRs) by David Berman on dates in November and December 2025, with individual ADR quantities and aggregated dollar values shown for each sale date.
T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to a Schedule 13G/A reporting a sizeable passive stake in Immunocore Holdings plc – ADR. As of 12/31/2025, it beneficially owned 5,961,227 ADRs, representing 11.8% of the outstanding class.
The firm reports sole voting and sole dispositive power over all 5,961,227 ADRs, with no shared voting or dispositive power. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunocore.
Immunocore Holdings plc announced that David Berman has decided to resign as Head of Research & Development, effective February 27, 2026, to pursue another opportunity. The company states that his resignation is not due to any disagreement over operations, policies, or practices.
Immunocore does not plan to appoint a direct replacement for Dr. Berman and instead intends to streamline and leverage its existing R&D structure. This signals a leadership transition within the research organization while maintaining continuity through the current R&D framework.
Immunocore Holdings plc reported a preliminary estimate of its cash, cash equivalents and marketable securities of about $864 million as of December 31, 2025. This figure is based on internal estimates, is unaudited and may change once full year-end financial statements are completed, and any adjustments identified by the company or its independent auditors could be material.
The company also outlined its strategic priorities for 2026 in a press release and updated its corporate presentation with business and strategy updates, including materials to be used at the 44th Annual J.P. Morgan Healthcare Conference. In addition, Immunocore published an updated pipeline chart for KIMMRAK (tebentafusp) and its development-stage therapeutic candidates. These materials are provided as exhibits and, where noted, are furnished rather than filed under securities law.
Immunocore Holdings plc (IMCR) reported insider transactions by its Head of R&D on Form 4. On November 24-25, 2025, the officer exercised employee share options with an exercise price of $17.46 per ordinary share and immediately sold the same number of shares in the market.
The transactions included exercising and selling 100 ordinary shares on November 24 at a sale price of $40.00 per share, and exercising and selling 18,020 ordinary shares on November 25 at a weighted average sale price of $40.03 per share. After these sales, the reporting person held no ordinary shares directly but continued to hold employee share options, including 118,670 options immediately exercisable and expiring on September 12, 2028. All trades were made under a Rule 10b5-1 trading plan adopted on May 9, 2025.
Immunocore Holdings plc furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent corporate updates.
The press release is included as Exhibit 99.1 and is incorporated by reference. The materials under Item 2.02 are being furnished, not filed, and therefore are not subject to Section 18 liabilities of the Exchange Act or automatically incorporated into other SEC filings.